NeuroCytonix Completes Clinical Trial of its NeuroCytotron Treatment of Cerebral Palsy
ROCKVILLE, MD. (PRWEB) JANUARY 30, 2023
NeuroCytonix, Inc. (the “Company” or “NeuroCytonix”) today announced that on January 19, 2023, its subsidiary NeuroCytonix Mexico has received a regulatory acknowledgment letter from the Mexican regulatory authority COFEPRIS – ref/memorandum number 223300ES450795/2023 – following the presentation of NeuroCytonix final report on its clinical trial on Cerebral Palsy NCX-CP-01.
COFEPRIS is member of the International Council of Harmonization (ICH) and Pharmaceutical Inspection Cooperation Scheme (PIC/S). In addition, COFEPRIS is a Level IV: National Regulatory Authority competent and efficient in the performance of the health regulatory functions recommended by PAHO / WHO.
The acknowledgment represents the legal and formal conclusion of the clinical trial, according to the methodology authorized by COFEPRIS. The resolution of the NCX-CP-01 clinical trial provides safety and efficacy data on investigational NeuroCytotron treatment of Cerebral Palsy. A manuscript detailing the results of this clinical trial is currently under preparation and will soon be submitted to several scientific journals.
The results of this clinical trial provide support for additional studies that will continue to evaluate the ongoing application of therapies with the NeuroCytotron in larger groups of patients, which will be supported by a Standard Operating Procedure where all cases will be recorded. This acknowledgment confirms that NeuroCytonix is a company that has formally concluded a clinical trial for its investigational NeuroCytotron treatment and is now registered in the National Registry of Research Companies in Mexico.
NeuroCytonix is an emerging biotechnology business founded in January 2017 by Dr. J Roberto Trujillo to develop and exploit transformational medical technologies for the regeneration of the nervous system. The Company’s technology and related protocols include Stroke, Autism, Cerebral Palsy and neurological consequences of Traumatic Brain Injury (TBI) and Covid19. The Company’s core technology, the NEUROCYTOTRON, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins which aid in the regeneration of brain cells.
The NeuroCytonix technology is based on the work of Dr. Rajah V Kumar, inventor of the Cytotron and a pioneer for more than 30 years in the field of biophysics, radiobiology, and regenerative tissue engineering.
The NeuroCytonix founder and CEO, Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, is a leader in clinical and basic neuroscience research and molecular virology for brain diseases and is transforming the status quo of healthcare for these previously believed incurable conditions.
NeuroCytonix has built a Research Center in Monterrey Mexico where it has trained and directed a clinical research team who has successfully implemented its first Cerebral Palsy clinical trial evaluating the safety and efficacy of the treatment.
Link to the full study on ClinicalTrials.gov.
Please visit http://www.neurocytonix.com for more information.
Laurent Lavigne du Cadet
Chief Financial Officer